GEGulcin Cengiz Ecemis

Gulcin Cengiz Ecemis

*This is an algorithmically generated author record based on publicly available information.

Gulcin Cengiz Ecemis has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Radiation-associated secondary brain tumors after conventional radiotherapy and radiosurgery

    by Gulcin Cengiz Ecemis, Aysegul Atmaca, Deniz Meydan

    Although there is not enough strong molecular evidence for radiation to be a causal factor for the development of secondary brain tumors, a relationship has still been found. There is a slight but significant 2-2.7% increased risk of secondary brain tumors after conventional radiotherapy. However, this risk is small and should not preclude the use of radiotherapy as an effective treatment for uncontrolled pituitary tumors. The risk of radiosurgery-associated secondary brain tumors has not been precisely determined. Taking into account the considerable number of patients who received radiosurgery worldwide and the small number of secondary brain tumors, radiosurgery seems to be a safe treatment modality. This review summarizes the pathogenesis, prevalence and characteristics of secondary brain tumors after conventional radiotherapy and stereotactic radiosurgery for pituitary adenomas.


  • Cases with adrenocortical carcinoma

    by Gulcin Cengiz Ecemis, Elif Kilic Kan, Cigdem Tura Bahadir, Aysegul Atmaca, Hulusi Atmaca, Ramis Colak

    Introduction: Adrenocortical carcinoma (ACC) is a rare cancer (estimated incidence, 0.7 to 2.0 cases per 1 million population per year) with a poor prognosis. Even after seemingly complete surgical resection, most patients develop recurrence within 5 years. The 5-year survival rate is <15% among patients with metastatic disease. Methods: We present the results of six patients with adrenocortical carcinoma followed in our clinic. Results: The mean age was 54 years and female/male ratio was 2/4. Tumor size ranges from 6 to 14 cm. At baseline, only one patient had high dehydroxyepiandrosterone-sulphate levels (Patient 1). Tumor was non-functional in 5 patients. One patient presented with Cushing’s syndrome and hypercortisolism was documented in her laboratory evaluations (Patient 4). All of them were treated with surgery. In one patient, tumor was bilateral and in others were on left adrenal. The patient with bilateral tumors had lung metastasis at diagnosis (Patient 3). Another patient developed lung metastasis 2 years after the operation (Patient 1). Patient 4 had lung metastasis and Patient 6 had lung, liver and lymph node metastasis. One patient was lost-to follow-up after the operation (Patient 5). Three patients died 5 months after the operation. Three out of six patients received mitotane after the operation. Two patients could not receive mitotane because of elevated liver enzymes (Patients 4 and 6). Patient 1 developed lung metastasis 2 years after the diagnosis and is now receiving chemotherapy (cisplatin-etoposide) with mitotane. This patient is being followed in our clinic for 53 months. Conclusion: Treatment options for advanced ACC are limited. Even after successful complete excision of the tumor, local or distant metastatic recurrences are frequent. However, some patients on regular follow-up and mitotane as adjuvant therapy may benefit from treatment as seen in Patient 1.

  • A patient osteogenesis imperfecta with osteoporosis

    by Gulcin Cengiz Ecemis, Elif Kilic Kan, Cigdem Tura Bahadir, Aysegul Atmaca, Hulusi Atmaca, Ramis Colak

    Introduction: Osteogenesis imperfecta (OI) is a congenital, generalized connective tissue disorder characterized by severe osteoporosis and bone fragility. OI is most commonly caused by mutations in genes encoding the α-1 and α-2 chains of type I collagen or proteins involved in posttranslational modification of type I collagen. Although, no controlled studies are done, bisphosphonates are used for the treatment of OI. I.v. bisphosphonates are reported to be more effective for pain conrol than oral bisphosphonates. Here, we report the results of a patient with OI and osteoporosis who received cyclic i.v. pamidronate. Case report: A 31 years old man with OI and osteoporosis admitted with generalized bone pain. He had been using alendronate 70 mg/week p.o. for 2 years with no improvement in bone mineral density (BMD) and pain. I.v. cyclic pamidronate was started at a dose of 60 mg/day for 3 days every 4 months. BMD was assessed at baseline, at 6 and 12 months of treatment. Short form-36 (SF-36) questionnaire was used to evaluate his quality of life at baseline and at 12 months. His vertabral BMD T-score was −4.2 and femur neck T-score was −2.0 at baseline. At 6th month, his vertabral BMD T-score was −3.6 and femur neck T-score was −1.6. At 12th month, his vertabral BMD T-score was −3.6 and femur neck T-score was −1.4. A significant improvement was observed in his SF-36 scores at 12th month. No adverse effects were observed due to treatment. Conclusions: OI is a rare disease and no treatment protocol has been shown to be superior to others. I.v. bisphosphonates may be better for pain control than oral bisphosphonates. This case shows the improvement of BMD and quality of life after 1 year treatment with i.v. pamidronate, which not achived with oral alendronate.

  • An acromegalic patient with giant tumor

    by Gulcin Cengiz Ecemis, Elif Kilic Kan, Cigdem Tura Bahadir, Aysegul Atmaca, Hulusi Atmaca, Ramis Colak

    Introduction: Acromegaly is a disease caused by excessive secretion of GH. The cause of acromegaly is GH secreting pituitary adenoam in 99% of the cases. It is estimated that 5% of pituitary adenomas become invasive and may grow to gigantic sizes (>4 cm in diameter). Here, we present a 31 years old acromegalic woman with a delayed diagnosis of a giant invasive pituiatary adenoma. Case report: A 31-year-old woman admitted to our hospital for oligomenorhea and loss of vision. She had a history of infertility for 10 years. She received IVF five times. Her FSH was 0.43 (3.5–12.5) mU/ml, LH was 0.07 (2.4–12.6) mU/ml, prolactin was 27 ng/ml (4.7–23) and IGF1 was 984 ng/ml (116–307 for her age). Her nadir GH level during a 75 g oral glucose tolerence test was 14.8 mg/dl. Pituitary magnetic resonance imaging revealed a 72×47×68 mm macroadenoma with necrotic componenets which invades suprasellar region and sphenoid sinus and destructs sphenoid bone. Despite a giant macroadenoma her thyrotrophes and corticotrophes were not affected. She had normal thyroid and adrenal fucntions. She had transcranial removal of the adenoma and histopathological diagnosis was eosinophilic somatotroph adenoma. Immunhistochemical staining was positive for GH. Postoperatively, she had severe hypernatremia and she was followed in intensive care unit. She died in her second postoperative day with severe electrolyte imbalance. Conclusions: Delayed diagnosis of acromegaly may lead to growth of a giant macroadenoma which then increases the likelihood of morbidity, postoperative complications and mortality.

  • The Results Of Pegvisomant Treatment In Acromegaly And Review of The Literature

    by Elif Kilic Kan, Gulcin Cengiz Ecemis, Cigdem Tura Bahadir, Aysegul Atmaca, Hulusi Atmaca, Ramis Colak